CNS Pharmaceuticals financials
$4.91−3.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.7M | -$5.0M | -$6.0M | -$3.3M | -$2.4M | -$4.3M | -$3.2M | -$5.6M | -$2.5M | -$3.5M | -$5.4M | -$4.5M |
| Net income | -$2.6M | -$4.9M | -$6.0M | -$3.2M | -$2.4M | -$4.3M | -$3.2M | -$5.6M | -$2.5M | -$3.5M | -$5.4M | -$4.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.38 | $-7.30 | $-9.65 | $-5.76 | $-6.42 | $-18.93 | $-36.68 | $-153.20 | $-4049.20 | $-12245.76 | $-620130.28 | $-32484.00 |
| EBITDA | -$2.7M | -$5.0M | -$6.0M | -$3.3M | -$2.4M | -$4.3M | -$3.2M | -$5.6M | -$2.5M | -$3.5M | -$5.4M | -$4.5M |
| Operating cash flow | -$3.5M | -$4.6M | -$3.1M | -$2.2M | -$5.3M | -$3.2M | -$5.5M | -$6.8M | -$1.7M | -$3.2M | -$2.5M | -$3.4M |
| Free cash flow | -$3.5M | -$4.7M | -$3.1M | -$2.2M | -$5.3M | -$3.2M | -$5.5M | -$6.8M | -$1.7M | -$3.2M | -$2.5M | -$3.4M |
| Diluted shares | 6.8M | 0.7M | 0.6M | 0.6M | 0.4M | 0.2M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.0M | $3.0M | $7.2M | $9.9M | $12.1M | $13.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $232.4K | $328.0K | $30.8K | $121.8K | $210.7K |
| Total assets | $21.9M | $4.7M | $8.6M | $11.9M | $14.5M | $13.7M |
| Total liabilities | $3.7M | $4.6M | $4.1M | $2.0M | $1.4M | $2.8M |
| Shareholders' equity | $18.2M | $70.7K | $4.5M | $9.9M | $13.1M | $11.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology